Neuropace (NPCE) CEO Becker received 45,880 shares
Insider transactions reported
Joel Becker (Chief Executive Officer at Neuropace Inc., NPCE) reported that they received 45,880 shares on May 15, 2026. After these transactions the filing shows 142,817 shares held directly.
- Reporting person
- Becker Joel
- Role
- CHIEF EXECUTIVE OFFICER
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 15, 2026 | Grant or award (A) | Common Stock1 | +45,880 | - | - | 142,817 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 15, 2026 | Grant or award (A) | Stock Option (Right to Buy)On 122,190 Common Stock2 | +122,190 | - | - | 122,190 direct |
Holdings before and after
- Common Stock: 96,937 to 142,817 direct
- Stock Option (Right to Buy): 0 to 122,190 direct
Footnotes from the filing
- 1. Each share is represented by a restricted stock unit ( RSU ). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.
- 2. 25% of the shares subject to the option vest on May 15, 2027. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Becker report in this NPCE Form 4?
Joel Becker (Chief Executive Officer at Neuropace Inc., NPCE) reported that they received 45,880 shares on May 15, 2026. After these transactions the filing shows 142,817 shares held directly.
How many NPCE shares does Becker hold after this filing?
The filing shows 142,817 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for NPCE
Across the 14 sessions after earlier NPCE headlines, the stock closed higher 11 times and lower 3 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NPCE | SPY |
|---|---|---|---|
| May 13, 2026 | NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance | +0.1% | +0.6% |
| Apr 30, 2026 | NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026 | +1.9% | +1.0% |
| Apr 27, 2026 | NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 | +2.7% | +0.2% |
| Apr 13, 2026 | NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference | +4.3% | +1.0% |
| Mar 6, 2026 | NeuroPace to Present at the Leerink Global Healthcare Conference | +3.2% | -1.3% |
| Mar 4, 2026 | NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook | +0.9% | +0.7% |
Earlier insider filings at NPCE
- Mar 25, 2026SEC Form 4 filed by Morrell Martha
- Mar 24, 2026SEC Form 4 filed by Geiger Uri
- Mar 24, 2026SEC Form 4 filed by Lacob Joseph
- Mar 23, 2026SEC Form 4 filed by Kumar Rakhi
- Mar 23, 2026SEC Form 4 filed by Fischer Frank M
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 2021
Follow NPCE and get a push notification the moment its next story breaks.